Didier Coeurnelle, co-chair of Heales and board member of the International Longevity Alliance, examines the latest advancements and obstacles in longevity research. He surveys lifestyle and environmental factors, healthcare disparities, and promising preventive and biotechnological approaches to support healthier aging globally.
Key points
Income, education, and environmental disparities drive unequal access to healthy aging resources.
Lifestyle factors and preventive healthcare serve as primary enablers for extending healthspan.
Emerging therapies—senolytics, NAD+ boosters, and drug repurposing—offer targeted approaches to combat cellular aging.
Why it matters:
By mapping barriers and enablers, this analysis informs integrative strategies to extend human healthspan and guide future longevity interventions.
Q&A
What are senescent cells?
How does metformin potentially affect aging?
What role do NAD+ boosters play in healthy longevity?
Why is preventive healthcare critical for longevity?
How can disparities affect healthy aging?
Read full article
Academy
Senolytics: A Key Approach in Longevity Science
Senolytics are a class of compounds designed to selectively target and eliminate senescent cells, which accumulate in tissues over time and contribute to age-related dysfunction. These cells enter a state of permanent growth arrest and secrete pro-inflammatory factors known as the senescence-associated secretory phenotype (SASP), impairing tissue repair and promoting chronic inflammation.
Researchers first recognized that clearing senescent cells in animal models could delay fibrosis, improve cardiac function, and restore regenerative capacity in aged organs. By reducing the SASP burden, senolytics alleviate local inflammation and improve tissue microenvironments.
How Senolytics Work- Target Identification: Senolytic compounds often inhibit pro-survival pathways that senescent cells rely on, such as BCL-2 family proteins, PI3K/AKT signaling, or the p53/p21 axis.
- Selective Apoptosis: After administration, senolytics induce programmed cell death in senescent cells while sparing proliferating or quiescent healthy cells.
- Clearance and Tissue Restoration: Immune system components then remove the apoptotic debris, leading to reduced inflammation and improved tissue repair.
Examples of Senolytic Agents- Dasatinib and Quercetin (D+Q): A combination therapy shown in mice to reduce senescent cell burden and improve cardiac and physical function.
- Navitoclax (ABT-263): A BCL-2 inhibitor that induces apoptosis in senescent cells but requires careful dosing due to potential thrombocytopenia.
- Fisetin: A natural flavonoid with senolytic activity and a favorable safety profile in preclinical studies.
Applications and Research AdvancesCurrent studies are exploring senolytics in models of osteoarthritis, pulmonary fibrosis, neurodegeneration, and metabolic disorders. Early-phase clinical trials are evaluating safety and efficacy of D+Q in conditions such as diabetic kidney disease and chronic obstructive pulmonary disease.
Safety ConsiderationsWhile senolytics have shown promising results in animals, human applications demand rigorous safety profiling. Potential risks include unintended apoptosis of non-senescent cells, immune reactions to cell debris, and off-target pharmacological effects. Dose optimization and targeted delivery systems, such as nanoparticle-based vehicles, are under development to mitigate these concerns.
Regulatory and Clinical PathwaysRegulatory agencies are establishing guidelines for clinical trials assessing senolytic therapies. Key endpoints include biomarker changes, functional improvements, and safety outcomes. Multidisciplinary collaborations between academic labs, biotech companies, and regulatory bodies are essential to accelerate development from the bench to bedside.
Senolytics represent a promising frontier in geroscience by addressing a root cause of aging at the cellular level. Ongoing research aims to translate preclinical successes into safe, effective therapies that extend healthspan and reduce age-related disease burden.
Understanding and harnessing senolytics is central to the emerging field of longevity biotechnology. By clearing accumulated senescent cells, these therapies offer a strategy to enhance tissue health, delay age-related pathologies, and improve overall resilience against degenerative diseases.
